Indo US Bio-Tech Ltd

While the Sensex advanced by 0.77% today, Indo US Bio-Tech Ltd slipped to a fresh 52-week low of Rs 84.83, marking a near 50% decline over the past year. This divergence highlights the stock’s ongoing struggles amid broader market strength.

Indo US Bio-Tech Ltd’s stock price declined to a fresh 52-week low of Rs.84.96 on 24 July 2026, marking a significant milestone in its ongoing downward trajectory. The stock has underperformed both its sector and broader market indices, reflecting a series of financial setbacks and technical weaknesses.

Indo US Bio-Tech Ltd’s stock price declined to a fresh 52-week low of Rs.85 on 16 Jul 2026, marking a significant milestone in its ongoing downward trajectory. The stock has underperformed its sector and broader market indices, reflecting a combination of recent financial results and technical indicators.

Indo US Bio-Tech Ltd is rated Sell by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed below reflect the company’s current position as of 16 July 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and technical outlook.

Indo US Bio-Tech Ltd’s stock price declined to a fresh 52-week low of Rs.85.66 on 8 July 2026, marking a significant milestone in its ongoing downward trajectory. The stock has underperformed both its sector and the broader market, reflecting a series of financial setbacks and market pressures over the past year.

Indo US Bio-Tech Ltd is rated Sell by MarketsMOJO, with this rating last updated on 19 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 05 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

A sharp decline in Indo US Bio-Tech Ltd has pushed the stock to a fresh 52-week low of Rs 86 on 30 Jun 2026, marking a significant 58% drop from its 52-week high of Rs 205.1. This downturn comes amid a backdrop of weakening quarterly financials and diminishing promoter confidence, even as the broader agricultural sector has shown resilience.

Indo US Bio-Tech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 June 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Indo US Bio-Tech Ltd is rated Sell by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 12 June 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and technical outlook.

Indo US Bio-Tech Ltd’s stock price declined to a fresh 52-week low of Rs.89.75 on 11 June 2026, marking a significant milestone in its ongoing downward trajectory. The stock has underperformed both its sector and broader market indices, reflecting a series of financial setbacks and market pressures over the past year.

Indo US Bio-Tech Ltd’s stock price declined sharply to a new 52-week low of Rs 90 on 10 June 2026, marking a significant milestone in its ongoing downward trajectory. The stock has underperformed both its sector and broader market indices, reflecting a series of financial setbacks and market pressures.

For the fifth straight session, Indo US Bio-Tech Ltd closed lower, breaching its 52-week low at Rs 94 on 3 Jun 2026, marking a 6.42% decline over the last three days and underperforming its sector by 2.46% today alone.

Indo US Bio-Tech Ltd., a micro-cap agricultural products company with a market capitalisation of ₹201.00 crores, reported a challenging fourth quarter for FY26, with net profit declining sharply to ₹1.97 crores from ₹3.00 crores in Q3 FY26, marking a 34.33% sequential decline. On a year-on-year basis, the profit contraction was even steeper at 46.47% compared to ₹3.68 crores in Q4 FY25. The stock, currently trading at ₹100.45, has struggled significantly over the past year, declining 41.45% whilst the broader market fell just 8.40%, underscoring deep investor concerns about the company's operational trajectory.

Indo US Bio-Tech Ltd is rated Sell by MarketsMOJO, with this rating last updated on 19 Jan 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 29 May 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and market performance.

Indo US Bio-Tech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 May 2026, providing investors with the latest insights into the company’s performance and outlook.

Indo US Bio-Tech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 May 2026, providing investors with the latest insights into the company’s performance and outlook.

Indo US Bio-Tech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 April 2026, providing investors with the latest insights into the company’s performance and outlook.

Indo US Bio-Tech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics presented here reflect the company’s current position as of 15 April 2026, providing investors with an up-to-date view of its fundamentals, returns, and overall outlook.

Indo US Bio-Tech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 April 2026, providing investors with the latest insights into the company’s performance and outlook.